

Final - February 22, 2021

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

February 24-25, 2021

<u>AGENDA ITEM</u>	<u>PRESIDER/PRESENTER(s)</u>
Wednesday, February 24, 2021	
9:30 Welcome & Introductions	Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
10:00 Rabies Vaccines Introduction Rabies pre-exposure prophylaxis: summary of background information Rabies pre-exposure prophylaxis: summary of Evidence to Recommendations Approach to rabies post-exposure prophylaxis Work group interpretations of data about rabies immune globulin and next steps for the WG	Dr. Sharon Frey (ACIP, WG Chair) Dr. Agam Rao (CDC/NCEZID) Dr. Agam Rao (CDC/NCEZID) Dr. Agam Rao (CDC/NCEZID) Dr. Agam Rao (CDC/NCEZID)
12:00	Break
12:30 Public Comment	
1:00 Votes Rabies Vaccines	Dr. Agam Rao (CDC/NCEZID)
1:20 Dengue Vaccine Introduction Results of dengue test independent evaluation Workgroup interpretation	Dr. Kathy Poehling (ACIP, WG Chair) Dr. Freddy Medina (CDC/NCEZID) Dr. Gabriela Paz-Bailey (CDC/NCEZID)
2:20 Tick-borne Encephalitis (TBE) Vaccine Introduction TBE epidemiology in TBE endemic areas TBE among US civilian travelers and laboratory workers TBE among military personnel and dependents Summary of risks of TBE for U.S. travelers and laboratory workers and next steps	Dr. Kathy Poehling (ACIP, WG Chair) Dr. Susan Hills (CDC/NCEZID) Dr. Erin Staples (CDC/NCEZID) Dr. Bruce McClenathan (DOD) Dr. Susan Hills (CDC/NCEZID)
3:30	Break
3:40 Ebola Vaccine Introduction Background on state designated Ebola Treatment Centers (ETC) and Laboratory Response Network (LRN) facilities and survey results Review of preliminary workgroup discussions	Dr. Sharon Frey (ACIP, WG Chair) Ms. Allison Joyce (CDC/NCEZID) Dr. Caitlin Cossaboom (CDC/NCEZID)
4:45 Hepatitis Vaccine Introduction Background Economic analysis	Dr. Sharon Frey (ACIP, WG Chair) Dr. Mark Weng (CDC/NCHHSTP) Dr. Eric Hall (Emory University)
5:30 Adjourn	
Thursday, February 25, 2021	
9:30 Welcome & Introductions	Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
9:40 Agency Updates	
10:00 Pneumococcal Vaccines Introduction Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage in US adults PCV20 Phase 2/3 study results in adults PCV15 Phase 2/3 study results in adults, including adults with underlying conditions Considerations for PCV15 and PCV 20 use in adults	Dr. Kathy Poehling (ACIP, WG Chair) Mr. Ryan Gierke (CDC/NCIRD) Dr. Wendy Watson (Pfizer) Dr. Ulrike Buchwald (Merck) Dr. Miwako Kobayashi (CDC/NCIRD)
12:00	Break
12:20 Zoster Vaccines Introduction Risk of Guillain-Barré syndrome (GBS) following recombinant zoster vaccine (RZV) RZV risk-benefit analysis Work group interpretation Introduction of the Evidence to Recommendations Framework for use of RZV in immunocompromised adults	Dr. Grace Lee (ACIP, WG Chair) Dr. Richard Forshee (FDA/CBER) Dr. Lisa Prosser (University of Michigan) Dr. Tara Anderson (CDC/NCIRD) Dr. Tara Anderson (CDC/NCIRD)

Final - February 22, 2021

1:30	Influenza Vaccines	
	Introduction	Dr. Keipp Talbot (ACIP, WG Chair)
	Influenza surveillance update	Dr. Lisa Grohskopf (CDC/NCIRD)
	Work group considerations	Dr. Lisa Grohskopf (CDC/NCIRD)
2:15		Break
2:25	Cholera Vaccine	
	Introduction	Dr. Pablo Sanchez (ACIP, WG Chair)
	Introduction to cholera and cholera vaccines	Dr. Jennifer Collins (CDC/NCEZID)
	Vaxchora safety and immunogenicity data	Dr. James McCarty (Emergent BioSolutions)
	Work group plans	Dr. Jennifer Collins (CDC/NCEZID)
3:25	Orthopoxviruses Vaccines	
	Introduction and use of Vaccinia virus vaccine in persons at risk for occupational exposure to orthopoxviruses: WG update	Dr. Beth Bell (ACIP, WG Chair)
	Workgroup considerations	Dr. Brett Petersen (CDC/NCEZID)
	Updated policy questions for EtR Framework and plan for next steps	Dr. Agam Rao (CDC/NCEZID)
5:00	Adjourn	

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
PCV15	15-valent pneumococcal conjugate vaccine
PCV20	20-valent pneumococcal conjugate vaccine
PEP	Post-exposure prophylaxis
PrEP	Pre-exposure prophylaxis
RZV	Recombinant zoster vaccine
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness